MorphoSys AG
Lena-Christ-Strasse 48
Martinsried
Munich
82152
Germany
Tel: 49-0-89-899-27-0
Fax: 49-0-89-899-27-222
Website: http://www.morphosys.com/
Email: info@morphosys.com
558 articles with MorphoSys AG
-
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/15/2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
-
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
3/9/2023
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
-
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
3/2/2023
MorphoSys AG announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.
-
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
3/2/2023
MorphoSys AG announces that it will stop work and operations on its pre-clinical research programs to optimize its cost structure.
-
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
1/9/2023
MorphoSys AG announced that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis - are expected to be available in early 2024.
-
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
1/5/2023
MorphoSys AG reported preliminary Monjuvi ® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023.
-
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
11/16/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2022.
-
With $120 million in backing, HI-Bio launched two assets licensed from MorphoSys AG, including the anti-CD38 antibody felzartamab and HIB210, aimed at severe immune-mediated diseases.
-
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
10/27/2022
MorphoSys AG announced that preliminary results from the ongoing Phase 1/2 study of tulmimetostat monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients.
-
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
10/27/2022
MorphoSys AG announced that its licensing partner, GSK plc, provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis.
-
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
10/21/2022
MorphoSys AG reported preliminary Monjuvi® U.S. net product sales for the third quarter of 2022 and provided an update to its financial guidance for 2022. Preliminary Monjuvi ® U.S. Net Product Sales are US$ 22.2 million for the third quarter of 2022 and US$ 64.1 million for the first nine months of 2022.
-
Fiona H. Marshall has been tapped as Novartis Institutes for BioMedical Research president after Jay Bradner's exit, while Tim Demuth will succeed Malte Peters for MorphoSys.
-
MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters
8/31/2022
MorphoSys AG announced that Malte Peters, M.D., the company’s Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022.
-
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
8/3/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the second quarter and first half year of 2022.
-
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
7/28/2022
MorphoSys AG ; will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST.
-
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
7/26/2022
MorphoSys AG reported preliminary U.S. net product sales of Monjuvi® for the second quarter 2022 and announced an update of its financial guidance for 2022 based on the preliminary unaudited consolidated results for the first six months 2022 and following the license agreements with Human Immunology Biosciences, Inc. for felzartamab and MOR210.
-
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
7/26/2022
MorphoSys AG announces an update of its financial guidance for 2022, after preliminary completion of the latest evaluation of MorphoSys' half year 2022 financial performance.
-
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
6/15/2022
I-Mab today announced two assets the Company has licensed from partner MorphoSys AG (FSE: MOR; NASDAQ: MOR), felzartamab (also known as TJ202/MOR202) and TJ210 (also known as MOR210), are advancing globally through new license agreements.
-
MorphoSys is having a busy week after entering into an equity participation agreement with HIBio and a supply agreement and clinical collaboration with Pfizer and Incyte.
-
MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.